# 510(k) SUMMARY

# Date of Summary

April 10, 2008

# Product Name

Platelia™ Lyme IgG

Sponsor

Bio-Rad   
3 Boulevard Raymond Poincaré   
92430 Marnes-la-Coquette   
France

# Correspondent

MDC Associates, LLC   
Fran White, Regulatory Consultant   
163 Cabot Street   
Beverly, MA 01915

# Substantially Equivalent Device

The Platelia™ Lyme IgG is substantially equivalent to the Mardx B. burgdorferi IgG Assay

Manufacturer: Mardx Diagnostics, Inc. Product: Mardx Lyme Disease EIA $( \mathrm { I g G } )$ Test  K894224

<table><tr><td rowspan=1 colspan=1>Product Attribute</td><td rowspan=1 colspan=1>Bio-Rad Platelia™ Lyme IgG</td><td rowspan=1 colspan=1>Mardx Lyme Disease Tests</td><td rowspan=1 colspan=1>SubstantialEquivalent</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The Platelia&quot; Lyme IgGassay is a qualitative testintended for use in thepresumptive detection ofhuman IgG antibodies toBorrelia burgdorferi inhuman serum or plasma. TheEIA system should be used totest serum or plasma frompatients with a history andsymptoms of infection with B.burgdorferi. All positive andequivocal specimens shouldbe re-tested with a highlyspecific, second-tier test suchas Western blot. Positivesecond-tier results aresupportive evidence oflinfection with B. burgdorferi.</td><td rowspan=1 colspan=1>The MarDx B. burgdorferiDisease EnzymeImmunoassay (EIA) IgGTest is a qualitative testintended for use in thepresumptive detection ofhuman IgG antibodies toBorrelia burgdorferi inhuman serum. This EIAsystem should be used totest serum from patientswith a history andsymptoms of infection withB. burgdorferi. All positiveand equivocal specimensshould be re-tested with ahighly specific, second-tiertest such as Western blot.Positive second-tier results</td><td rowspan=1 colspan=1>√</td></tr></table>

Page 8 of 15   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>The diagnosis of Lymedisease should be made basedon history and symptoms(such as erythema migrans),and other laboratory data, inaddition to the presence ofantibodies to B. burgdorferi.Negative results (either first orsecond-tier) should not beused to exclude Lyme disease.</td><td rowspan=1 colspan=1>are supportive evidence ofinfection with B.burgdorferi. The diagnosisof Lyme disease should bemade based on history andsymptoms (such aserythema migrans), andother laboratory data, inaddition to the presence ofantibodies to B.burgdorferi. Negativeresults (either first orsecond-tier) should not beused to exclude Lymedisease.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Plasma or serum</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>√</td></tr><tr><td rowspan=1 colspan=1>Testmethodology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>√</td></tr></table>

# PRODUCT DESCRIPTION

The Platelia™ Lyme IgG Assay is a qualitative assay for the detection of human IgG antibodies to Borrelia burgdorferi in human serum or plasma.

# INTENDED USE

The Platelia™M Lyme IgG Test is a qualitative test intended for use in the presumptive detection of human IgG antibodies to Borrelia burgdorferi in human serum or plasma $\mathrm { R } _ { 3 }$ EDTA, sodium heparin or sodium citrate). The EIA system should be used to test serum or plasma from patients with a history and symptoms of infection with B. burgdorferi. All positive and equivocal specimens should be retested with a specific, second-tier test such as Western blot. Positive second-tier results are supportive evidence of infection with B. burgdorferi. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to B. burgdorferi. Negative results (either first or second-tier) should not be used to exclude Lyme disease.

# SUMMARY OF TECHNOLOGY

The PlateliaTM Lyme IgG Assay uses an indirect ELISA immuno-enzymatic method. Inactivated antigens of Borrelia burgdorferi B31 are used for coating the microplate. A monoclonal antibody labeled with peroxidase which is specific for human gamma chains (anti-IgG) is used as the conjugate.

# PERFORMANCE DATA

# Bio-Rad confirms that any/all data provided in this submission may be released upon request.

# Sensitivity

# a. Retrospective study

Oy   u Platelia™Lyme Gassay.Diseae stae was available r each sampe testdDta below umarizes thevral sensitivity of the assay, and the sensitivity considering the different stages of Lyme disease.

Performance of the Platelia™ Lyme IgG Assay on retrospective samples   

<table><tr><td colspan="2"></td><td>Positive</td><td>Equivocal</td><td>Negative</td><td>Total</td><td>% Sensitivity (1)</td></tr><tr><td rowspan="3">PlateliaT Lyme IgG</td><td>Early Stage</td><td>55</td><td>16</td><td>49</td><td>120</td><td rowspan="3">59.2% (71/120) $Cr({2 [50.2, 67.6] 60.6% (20/33) CI [43.7, 75.3] 100.0% (13/13)</td></tr><tr><td>Disseminated Stage</td><td>18</td><td>2</td><td>13</td><td>33</td></tr><tr><td>Late Stage</td><td>13</td><td>0</td><td>0</td><td>13</td></tr><tr><td></td><td>All Stages</td><td>86</td><td>18</td><td>62</td><td>166</td><td>CI [77.2, 100] 62.7% (104/166) CI [54.5, 69.0]</td></tr></table>

# (1) Equivocal results were considered as positive for calculation of sensitivity. (2 $C I = 9 5 \%$ Confidence Interval

# b. CDC Panel

The followig oation s from a seru panelbtaid from the DC and tested by the Platel™ Lyme IGKit. The results ae presented as a means to convey frtherinformation on the perfrmance o this assay wiha maske, cz  pTh  o  Te results obtained on Platelia™™ Lyme IgG and a marketed device.

Page 10 of 15   
Performance of the Platelia™™ Lyme $\mathbf { I g } \mathbf { G }$ Assay on Lyme CDC panel   

<table><tr><td rowspan=2 colspan=1>Timefromonset</td><td rowspan=1 colspan=4>Platelia™ Lyme IgG</td><td rowspan=1 colspan=4>Predicate Lyme IgG EIA Assay</td></tr><tr><td rowspan=1 colspan=1>Positiveorequivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>%agreementwithclinicaldiagnosis71)</td><td rowspan=1 colspan=1>Positiveorequivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>%agreementwithclinicaldiagnosis1)</td></tr><tr><td rowspan=1 colspan=1>Normals</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.0%(5/5)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.0%(5/5)</td></tr><tr><td rowspan=1 colspan=1>0-1Month</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>40.0%(2/5)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>60.0%(3/5)</td></tr><tr><td rowspan=1 colspan=1>1-2Months</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>62.5%(5/8)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>37.5%(3/8)</td></tr><tr><td rowspan=1 colspan=1>3-12Months</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>17(2)</td><td rowspan=1 colspan=1>58.8%(10/17)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>55.6%(10/18)</td></tr><tr><td rowspan=1 colspan=1>&gt; 1 Year</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>100.0%(8/8)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>87.5%(7/8)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>43 (2)</td><td rowspan=1 colspan=1>69.8%(30/43)</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>63.6%(28/44)</td></tr></table>

quival saple consered as posiive

# Prospective study

A prpecive uy wa onducte  spl colleed at ent ondei eg UniteS and routie esterymisas.The ate™ym ssay as evaluat  cron wi he - ye p n osiiaELSA est  WstBo summarized below.

Performance of the Platelia™ Lyme IgG Assay on prospective samples   

<table><tr><td rowspan="2"></td><td colspan="3">Platelia™ Lyme IgG</td></tr><tr><td>Positive</td><td>Equivocal</td><td>Negative</td></tr><tr><td>Site 1 (n=339)</td><td>45</td><td>18</td><td>276</td></tr><tr><td>Site 2 (n=100)</td><td>10</td><td>7</td><td>83</td></tr><tr><td>Total (n=-439)</td><td>55</td><td>25</td><td>359</td></tr></table>

Page 11 of 15   
Results of Wester-Blot on prospective samples found positive or equivocal with the Platelia™ Lyme IG Assay   

<table><tr><td></td><td colspan="3">Lyme IgG Platelia™ Lyme IgG Western Blot</td></tr><tr><td>Site 1</td><td>Positive or Equivocal</td><td>IgG Positive</td><td>Agreement samples (%)</td></tr><tr><td rowspan="2">(n=339) Site 2 (n=100)</td><td>61 (l)</td><td>6 (1)</td><td>9.8%</td></tr><tr><td>17</td><td>3</td><td>17.6%</td></tr><tr><td>Total (n=439)</td><td>78</td><td>9</td><td>11.5%</td></tr></table>

# Analytical Specificity

Analyclsechessy w e y t pn  taim bloo don100 saploe satsier dmirymiseNevrend Lsa oeoestse yat proviizhe e positive/equivocal results obtained in each category.

Analytical specificity of Platelia™ Lyme IgG Assay in blood donors   

<table><tr><td rowspan=1 colspan=1>canmaGlo</td><td rowspan=1 colspan=1>Endemic</td><td rowspan=1 colspan=1>Non-Endemic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Number of samples tested</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>183</td></tr><tr><td rowspan=1 colspan=1>Positive or Equivocal</td><td rowspan=1 colspan=1>1.2%(1/83)</td><td rowspan=1 colspan=1>0.0%(0/100)</td><td rowspan=1 colspan=1>0.5%(1/183)</td></tr></table>

# Precision

# a. Intra-assay precision

I 0 e  . Tha Institute guidance (formerly NCCLS) EP-SA2 revised November 2004. Mean Ratio, Standard Deviation (SD) and Coefficient of Variation $( \% C V )$ for each of the seven specimens are provided.

Intra-assay precision of Platelia™ Lyme IgG

<table><tr><td colspan="2"></td><td>N</td><td>Mean Ratio</td><td>SD</td><td>CV %</td></tr><tr><td rowspan="3">Near the Cut- Off samples</td><td>Sample 1</td><td>20</td><td>0.85</td><td>0.045</td><td>5.3%</td></tr><tr><td>Sample 2</td><td>20</td><td>1.00</td><td>0.050</td><td>5.4%</td></tr><tr><td>Sample 3</td><td>20</td><td>1.19</td><td>0.111</td><td>9.4%</td></tr><tr><td rowspan="3">Samples spanning the Platelia™ Lyme</td><td>Sample 4</td><td>30</td><td>0.20</td><td>0.010</td><td>6.4%</td></tr><tr><td>Sample 5</td><td>30</td><td>0.95</td><td>0.082</td><td>8.6%</td></tr><tr><td>Sample 6</td><td>30</td><td>1.38</td><td>0.116</td><td>8.4%</td></tr><tr><td>IgG assay range</td><td>Sample 7</td><td>30</td><td>6.31</td><td>0.134</td><td>2.1%</td></tr></table>

# Inter-assay precision

Iva n ual t wia u  ysThe a /w   e, Standard Deviation (SD) and Coefficient of Variation $( \% C V )$ for each of the seven specimens are provided.

Inter-assay precision of Platelia™ Lyme IgG

<table><tr><td></td><td>N</td><td>Mean Ratio</td><td>SD</td><td>CV %</td></tr><tr><td>Negative 1</td><td>40</td><td>0.19</td><td>0.032</td><td>16.7%</td></tr><tr><td>Negative 2</td><td>40</td><td>0.23</td><td>0.025</td><td>10.9%</td></tr><tr><td>Low equivocal</td><td>40</td><td>0.85</td><td>0.115</td><td>13.5%</td></tr><tr><td>High equivocal</td><td>40</td><td>1.16</td><td>0.208</td><td>18.0%</td></tr><tr><td>Medium Positive</td><td>40</td><td>3.92</td><td>0.335</td><td>8.5%</td></tr><tr><td>High Positive</td><td>40</td><td>6.67</td><td>0.650</td><td>9.7%</td></tr></table>

# Inter-site precision

I y un bei pe bya t eTe atSp O/CO) was eteri r ac sapMen Ratio, Standard Deviation (SD) and Coefficient of Variation $( \% C V )$ for each of the six specimens are provided. Total assay precision of Platelia™ Lyme IgG

Page 13 of 15   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Between-DayPrecision</td><td rowspan=1 colspan=3>Total Precision</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Site 1NegativeSite 21Site 3</td><td rowspan=1 colspan=1>0.320.440.45</td><td rowspan=1 colspan=1>0.0330.0450.050</td><td rowspan=1 colspan=1>10.4%9.5%11.0%</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>18.6%</td></tr><tr><td rowspan=1 colspan=1>Site 1NegativeSite 22Site 3</td><td rowspan=1 colspan=1>0.310.430.41</td><td rowspan=1 colspan=1>0.0310.0280.060</td><td rowspan=1 colspan=1>9.8%6.6%14.6%</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.068</td><td rowspan=1 colspan=1>17.6%</td></tr><tr><td rowspan=1 colspan=1>Low    Site 1Positive Site 21     Site 3</td><td rowspan=1 colspan=1>1.531.621.62</td><td rowspan=1 colspan=1>0.1220.2240.243</td><td rowspan=1 colspan=1>8.0%13.8%15.0%</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>0.202</td><td rowspan=1 colspan=1>12.7%</td></tr><tr><td rowspan=1 colspan=1>Low    Site 1Positive  Site 22     Site 3</td><td rowspan=1 colspan=1>1.411.451.48</td><td rowspan=1 colspan=1>0.1150.1550.108</td><td rowspan=1 colspan=1>8.1%10.7%7.3%</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.128</td><td rowspan=1 colspan=1>8.9%</td></tr><tr><td rowspan=1 colspan=1>High   Site 1Positive  Site 21     Site 3</td><td rowspan=1 colspan=1>3.063.193.08</td><td rowspan=1 colspan=1>0.2560.3570.267</td><td rowspan=1 colspan=1>8.4%11.2%8.7%</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>0.296</td><td rowspan=1 colspan=1>9.5%</td></tr><tr><td rowspan=1 colspan=1>High   Site 1Positive  Site 22     Site 3</td><td rowspan=1 colspan=1>3.373.403.36</td><td rowspan=1 colspan=1>0.4980.3350.344</td><td rowspan=1 colspan=1>14.8%9.9%10.2%</td><td rowspan=1 colspan=1>3.37</td><td rowspan=1 colspan=1>0.391</td><td rowspan=1 colspan=1>11.6%</td></tr></table>

# Cross Reactivity

Serafom ials Uni Sta  herhyise w tesel cross-reactivity with the PlateliaTM Lyme IgG assay. Results for sixteen conditions are presented.

Cross-reactivity conditions with Platelia™ Lyme IgG

<table><tr><td rowspan=1 colspan=1>Disease Condition</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Positive / Equivocal</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>H. pylori</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>CMV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>EBV IgG</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HSV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Measles IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Mumps IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>VZV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HIV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Antinuclear Antibodies (ANA)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Human anti-mouse antibodies(HAMA)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr></table>

Page 14 of 15   

<table><tr><td rowspan=1 colspan=1>CRP</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>SLE</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr></table>

# MATRIX COMPARISON STUDY

Pasavess u cpns wee pere wi  panel5 ps 1neativeand 3 posiv  eul samples). See table 10 below.   
istribution of percent difference versus serum

<table><tr><td colspan="2"></td><td>&lt;10%</td><td>≥10% to ≤20%</td><td>&gt;20%</td><td>Mean of differences</td></tr><tr><td rowspan="3">Negative samples (n=12)</td><td>K3 EDTA</td><td>16.7%</td><td>8.3%</td><td>75.0%</td><td>-16.7%</td></tr><tr><td>Na Heparin</td><td>33.3%</td><td>0.0%</td><td>66.7%</td><td>-12.4%</td></tr><tr><td>Na Citrate</td><td>8.3%</td><td>8.3%</td><td>83.4%</td><td>-20.9%</td></tr><tr><td>Equivocal or</td><td>K3 EDTA</td><td>46.1%</td><td>15.4%</td><td>38.5%</td><td>2.9%</td></tr><tr><td rowspan="3">Positive samples (n = 13)</td><td>Na Heparin</td><td>61.5%</td><td>15.4%</td><td>23.1%</td><td>0.6%</td></tr><tr><td>Na Citrate</td><td>38.5%</td><td>46.1%</td><td>15.4%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>0.0%</td></tr></table>

Alarevratn has bee servenegtiv plasa card tnegative rut wihoutchngesuls H   ou interpretation.

# INTERFERING SUBSTANCES

0 yozmp p0L fches.

# MAY - 8 2008

MDC Associates, LLC c/o Ms. Fran White Regulatory Consultant 163 Cabot Street Beverly, MA 01915

Re: k080012 Trade/Device Name: PlateliaTM Lyme IgG Assay Regulation Number: 21 CFR $\ S$ 866.3830 Regulation Name: Treponema pallidum treponemal test reagents. Regulatory Class: Class II Product Code: LSR Dated: April 10, 2008 Received: April 14, 2008

Dear Ms. White:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act: The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): K080012

Device Name:

# Platelia™ Lyme IgG

Indications for Use:

The Platelia" Lyme IgG assay is a qualitative test intended for use in the presumptive detection of human IgG antibodies to Borrelia burgdorferi in human serum or plasma ( ${ \bf K } _ { 3 }$ EDTA, sodium heparin or sodium citrate). The EIA test system should be used to test serum or plasma from patients with a history and symptoms of infection with B. burgdorferi. All positive and equivocal specimens should be re-tested with a specific, second-tier test such as Western blot. Positive second-tier results are supportive evidence of infection with B. burgdorferi. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to B. burgdorferi. Negative results (either first or second-tier) should not be used to exclude Lyme disease.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/44c0ceed6eb62264422da7f21fe4e32e1e23fb50293972e4e4b4bd0eebbf8482.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

Page 1 of 1